Isoform-Selective TGFβ1 Antibodies for Latent Complex Activation Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TGFβ inhibitors face safety and efficacy challenges, with systemic inhibition leading to severe toxicities and lack of effective therapeutics for conditions like cancer and fibrosis.
Innovation Solution
Development of high-affinity, isoform-selective monoclonal antibodies that target the latent pro-protein complex of TGFβ1, inhibiting its activation with high potency and specificity, while maintaining safety profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic TGFβ inhibition is used to treat diseases, then therapeutic efficacy is improved, but severe toxicities occur
Solution Approach 1:
The patent applies local quality by developing isoform-selective inhibitors that specifically target TGFβ1 while sparing TGFβ2 and TGFβ3. This selective inhibition allows therapeutic efficacy against TGFβ1-driven diseases while avoiding toxicities associated with pan-TGFβ inhibition, as different isoforms have different physiological roles and tissue distributions
Solution Approach 2:
The patent segments the TGFβ superfamily into distinct isoforms (TGFβ1, TGFβ2, TGFβ3) and develops inhibitors that selectively target only TGFβ1. This segmentation enables differential modulation of TGFβ signaling pathways, achieving therapeutic benefits while minimizing adverse effects from non-selective inhibition
2Reliability
If TGFβ inhibitors are developed for cancer and fibrosis, then disease progression is halted, but serious side effects occur leading to program discontinuation
Solution Approach 1:
The patent implements local quality through isoform-selective TGFβ1 inhibition, creating therapeutics that specifically address TGFβ1-mediated disease progression in cancer and fibrosis while preserving the beneficial functions of TGFβ2 and TGFβ3, thereby reducing serious side effects associated with broad TGFβ pathway inhibition
3Power
If monoclonal antibodies target latent pro-protein complex of TGFβ1, then activation is blocked with high potency, but antibody design complexity increases
Solution Approach 1:
The patent applies preliminary action by designing monoclonal antibodies that bind to the latent pro-protein complex of TGFβ1 before activation occurs. This preemptive binding prevents activation and downstream signaling with high potency, blocking the pathway at its source rather than requiring intervention at multiple downstream points
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively block TGFβ1 activation, reducing disease-associated gene expression and immunosuppressive cell populations, enhancing anti-tumor effects, and achieving synergistic benefits with cancer therapies, with improved safety and efficacy in preclinical models.
Implementation Method 1
a monoclonal antibody or antigen-binding fragment thereof that is capable of binding to each of the following human LLC complexes with a KD of ≤10 nM
Data Source
AI summary
Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1 with high potency. Related compositions, methods and therapeutic use are also disclosed.